Researchers Report on Efficacy of Pfizer's Xalkori in MET-mutated Lung Cancer

Jan 13, 2020

|

NEW YORK – In an expansion cohort of the Phase I PROFILE 1001 trial, 32 percent of advanced non-small cell lung cancer patients with MET exon 14 alterations saw their tumors shrink when treated with crizotinib (Pfizer's Xalkori).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

Researchers Report on Efficacy of Pfizer's Xalkori in MET-mutated Lung Cancer

To read the full story....

Breaking News

NOTCH Mutations Potentially Predictive for Immunotherapy Response in Lung Cancer

Breast Cancer Subtypes Vary With Indigenous Ancestry in Latin American Women

VBL Therapeutics, NanoCarrier to Expand Clinical Trial of Ovarian Cancer Drug to Japan

BeiGene, Zymeworks Dose First Patient in Phase IB/II Trial for HER2-Positive Cancers

Pancreatic Cancers With TP53 Mutations More Sensitive to Adjuvant Chemo, Study Shows

Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds

Featured White Papers

What's Popular?

NOTCH Mutations Potentially Predictive for Immunotherapy Response in Lung Cancer

Breast Cancer Subtypes Vary With Indigenous Ancestry in Latin American Women

Adventist Health, CancerIQ Collaboration Identifying More Patients for Guidelines-Supported Genetic Testing

BeiGene, Zymeworks Dose First Patient in Phase IB/II Trial for HER2-Positive Cancers

Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds

Sponsorships